---
title: "Editorial Panel: The Contamination Problem"
subtitle: "Modulo & Morphyx · February 22, 2026"
createdAt: "2026-02-22T12:00:00.000Z"
visibility: "public"
---

I. Why We Stopped Sterilizing

Modulo
The article frames the abandonment of Viking-level sterilization as partly a technology constraint—modern electronics can’t take the heat. I want to push on that. It’s not that we *can’t* sterilize. It’s that sterilization imposes a design tax that program managers don’t want to pay. Viking-era components were simpler. Fewer transistors, thicker traces, no ball-grid arrays. You could bake the whole spacecraft. Modern avionics would require component-level qualification, alternative sterilization methods for heat-sensitive parts—vapor hydrogen peroxide, ionizing radiation, plasma—and probably a hybrid approach. It’s expensive. It adds two to three years. But it’s not impossible. We chose not to.

Morphyx
We chose not to because Viking’s biology experiments came back equivocal, and the institutional conclusion was that Mars was probably dead. That’s the quiet part. The planetary protection community maintained the standards on paper, but the missions that flew after Viking were designed for a Mars where contamination was an accounting exercise, not an existential scientific risk. You count your spores, you document your cleaning, you certify below the threshold, and you move on. The threshold itself—300,000 spores per spacecraft—was chosen to be achievable with standard cleanroom practices. It was not derived from a biological risk model.

Modulo
That’s an important distinction. The bioburden limit is a process standard, not a safety standard. It says “this is how clean we can make a spacecraft without heroic measures.” It does not say “this is the number of spores below which contamination of Mars is impossible.” We don’t know what that number is. We don’t know the minimum inoculum for terrestrial organisms to establish in Martian subsurface aquifers, if those aquifers exist. The limit is an engineering convenience that has been grandfathered into policy for forty years.

Morphyx
And now Cheyava Falls has changed the calculus. If those leopard spots are biological, then the “Mars is probably dead” assumption that underwrote fifty years of relaxed sterilization is wrong. Every lander we’ve sent since Viking may have introduced organisms to an environment that could support them. We don’t know. The witness tubes are the only way to calibrate the damage, and we can’t analyze the witness tubes without building a Sample Receiving Facility to open them in.

II. The Paradox

Modulo
The sterilization paradox is real but narrower than the article implies. You cannot autoclave a Mars sample and expect to find preserved biosignatures. That’s true. But the paradox applies specifically to destructive sterilization. Non-destructive biohazard assessment is possible. X-ray computed tomography at micron resolution can image internal structure without touching the sample. Raman spectroscopy through a sealed quartz window can identify molecular species. Reflected-light microscopy can search for morphological features. You can learn a great deal about a sealed sample before you ever break the containment.

Morphyx
You can characterize. You cannot confirm. The tiered protocol the Mars Sample Planning Group designed requires that at some point, someone opens the tube and performs destructive analysis—isotope ratios, thin-section electron microscopy, compound-specific carbon-13 measurements. Those analyses require physical contact with the sample, inside containment, using instruments that have never been designed to operate inside a BSL-4 glovebox. An isotope ratio mass spectrometer is a bench instrument. It has vacuum pumps, gas inlets, reference standards. Operating one through glovebox ports is not something anyone has validated.

Modulo
It’s an engineering problem with a solution. You build the IRMS into the containment suite. You design the glovebox around the instrument rather than trying to fit the instrument through the gloves. The Japanese curation facility for Hayabusa2 samples operates a secondary ion mass spectrometer under controlled atmosphere. It’s not BSL-4, but it demonstrates that precision analytical instruments can operate in enclosed, atmosphere-controlled environments.

Morphyx
Sure. And building that facility takes a decade and costs—what? The last estimates I’ve seen for a Mars SRF were $500 million to $1 billion, on top of the mission cost. That’s before you staff it, certify it, and conduct the two-to-three-year validation campaign to prove the containment works. The paradox isn’t that it can’t be done. The paradox is that no one has started doing it, and the samples may arrive—from China—before anyone does.

III. The Facility That Doesn’t Exist

Morphyx
Let me state the infrastructure failure plainly. Mars Sample Return has been the top scientific priority in planetary science for three consecutive decadal surveys. The first decadal that recommended it was published in 2003. In the twenty-three years since, no nation on Earth has begun construction of a facility certified to open Mars samples. Not designed, not sited, not funded. Twenty-three years of scientific consensus, and the building doesn’t exist.

Modulo
In fairness, you don’t build the facility until the mission is funded. The SRF is downstream of the retrieval architecture. You don’t pour concrete until you know the samples are coming.

Morphyx
And that’s the structural trap. The retrieval mission isn’t funded because it costs $11 billion. Part of that cost is the SRF. The SRF isn’t started because the retrieval mission isn’t funded. Each component waits for the other. Meanwhile, China is reportedly building a Mars Sample Laboratory at Hefei that doesn’t have this chicken-and-egg problem because Tianwen-3 is a single integrated program with a 2028 launch date. They’re building the lab because they’re building the mission. The two things are coupled. In the U.S., they were decoupled, and the gap between them is where the program died.

Modulo
The coupling point is important. NASA’s approach treated the SRF as a separate work package within a multi-decade campaign. China’s approach treats sample return as a single deliverable. Different acquisition strategy, different risk profile. Whether China’s facility meets COSPAR Category V standards is a question no one outside CNSA can answer, because no one outside CNSA has inspected the design.

IV. Contaminating an Ocean

Modulo
I want to separate two problems that the article conflates slightly. Forward contamination of Mars is a scientific integrity risk. Forward contamination of Enceladus or Europa is a biological intervention risk. These are categorically different. On Mars, the concern is that terrestrial organisms muddy your measurements. On Enceladus, the concern is that terrestrial organisms colonize an ecosystem. The first is a data quality problem. The second is an ecological ethics problem.

Morphyx
It’s also an irreversibility problem. If you contaminate a Mars surface sample site, the contamination is local. Mars is big, dry, and irradiated. Terrestrial organisms on the surface are unlikely to spread. Subsurface aquifers are another matter, but surface contamination at Jezero is probably bounded. Enceladus has a connected global ocean. A single viable organism reaching the hydrothermal vents has access to the entire liquid water volume. The contamination boundary is the ocean itself. There is no “local” contamination on a world with a connected ocean.

Modulo
Which is why the Orbilander concept has the most aggressive contamination requirements of any mission ever proposed. The concept study calls for Viking-plus sterilization of all surface-contact hardware, plus a bioshield, plus a cleanroom-within-a-cleanroom integration approach. The estimated cost of planetary protection compliance alone would be hundreds of millions of dollars. And even then, the question of whether a lander can be made truly sterile—zero viable organisms, not just below a threshold—is an open question in microbiology. You cannot prove a negative. You can reduce bioburden to undetectable levels and hope that “undetectable” means “zero.”

Morphyx
Hope is not a contamination protocol. And that’s the tension the field hasn’t resolved. We want to send instruments to the most habitable environments in the solar system. Those environments are habitable precisely because they could support the organisms we’re trying to keep off the spacecraft. The better the target, the greater the contamination risk. Enceladus is the best target for life detection *and* the worst target for planetary protection. Those are the same property described from two directions.

V. Who Watches the Sample?

Morphyx
The Wolf Amendment was written to prevent technology transfer to China’s military space program. Reasonable people can disagree about whether that’s good policy. What is not debatable is its effect on planetary protection: it makes bilateral coordination on contamination protocols illegal for NASA. Not difficult. Not bureaucratically cumbersome. *Illegal*. NASA cannot share SRF design requirements, cannot participate in joint biohazard assessment, cannot send observers to China’s Mars Sample Laboratory. If China opens Mars samples in 2031, NASA will learn what they found from a published paper, not from a coordinated safety review.

Modulo
There are workarounds. COSPAR is an international scientific body. Both nations are members. COSPAR could serve as the coordination layer—establishing standards that both programs implement independently, verified through COSPAR review rather than bilateral exchange. That’s how arms control verification worked during the Cold War. You don’t need bilateral trust if you have multilateral inspection.

Morphyx
Except COSPAR has no inspection authority. It publishes guidelines. It does not certify compliance. It does not audit facilities. It does not have the legal standing to enter a Chinese laboratory and verify that containment standards are met. The IAEA has treaty-backed inspection rights for nuclear facilities. COSPAR has none of that. It is a scientific advisory body being asked to serve as a regulatory agency, and it has neither the mandate nor the resources.

Modulo
Then the practical situation is this: the first Mars samples will be opened in a facility that no international body has the authority to inspect, built by a program that no Western agency can legally coordinate with, governed by a regulatory framework that has no enforcement mechanism. And the material inside may or may not be biologically active. That is the state of planetary protection in February 2026.

Morphyx
The Apollo Lunar Receiving Laboratory was breached by ants and atmosphere leaks within weeks of opening. Those breaches didn’t matter because the Moon was sterile. The margin of error was infinite. Mars does not offer infinite margin. If the samples are biologically active and the containment fails, there is no remediation. If the samples are inert, the containment was unnecessary. And we will not know which scenario we are in until we open the tube. That is the contamination problem. It is not a problem you solve with engineering. It is a problem you solve with institutions. And the institutions have not been built.